Miguel Sanmamed, PhD, MD
Assistant Professor AdjunctAbout
Research
Publications
2024
Targeting T-cell costimulation to the surface of tumor cells.
Eguren-Santamaría I, Sanmamed M, Molero-Glez P, Perez-Gracia J, Melero I. Targeting T-cell costimulation to the surface of tumor cells. Clinical Cancer Research 2024 PMID: 39531541, DOI: 10.1158/1078-0432.ccr-24-3003.Peer-Reviewed Original ResearchT lymphocytesTumor cellsTargeting T-cell costimulationSurface of tumor cellsT cell costimulationProportion of patientsT cell activationAntitumor responseT cellsSolid tumorsSurface antigensActivator receptorSignal 2CostimulationTumorTarget specificityCellsCD137HER2Novel evidencePatientsAntigenReceptorsImmunogenicity and Efficacy of Personalized Adjuvant mRNA Cancer Vaccines.
Berraondo P, Cuesta R, Sanmamed M, Melero I. Immunogenicity and Efficacy of Personalized Adjuvant mRNA Cancer Vaccines. Cancer Discovery 2024, 14: 2021-2024. PMID: 39485256, DOI: 10.1158/2159-8290.cd-24-1196.Peer-Reviewed Original ResearchOA10.05 Phase I Trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3-Positive Tumors: Patients with LCNEC
Wermke M, Gambardella V, Kuboki Y, Alese O, Morgensztern D, Sayehli C, Sanmamed M, Arriola E, Wolf J, Villaruz L, Studeny M, Bouzaggou M, Fang X, Felip E. OA10.05 Phase I Trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3-Positive Tumors: Patients with LCNEC. Journal Of Thoracic Oncology 2024, 19: s32. DOI: 10.1016/j.jtho.2024.09.059.Peer-Reviewed Original ResearchA phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer
Planchard D, Wolf J, Solomon B, Sebastian M, Wermke M, Heist R, Sun J, Min Kim T, Reguart N, Sanmamed M, Felip E, Garrido P, Santoro A, Bootle D, Couillebault X, Gaur A, Mueller C, Poggio T, Yang J, Moschetta M, Dooms C. A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer. Lung Cancer 2024, 197: 107964. PMID: 39383771, DOI: 10.1016/j.lungcan.2024.107964.Peer-Reviewed Original ResearchNon-small cell lung cancerCell lung cancerBRAF-mutated non-small cell lung cancerLung cancerDose-escalation/dose-expansion studyTreatment-related adverse eventsAntitumor activityDose-limiting toxicityNRAS-mutant melanomaMEK1/2 inhibitor trametinibPartial responseInhibitor trametinibFrequent gradeSafety profileAdverse eventsPharmacodynamic effectsTrametinibGenetic alterationsMedian reductionPan-RAFIncreased lipasePatientsSecondary objectivesMRNA levelsEvaluate toleranceSequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma.
Ascierto P, Mandalà M, Ferrucci P, Guidoboni M, Rutkowski P, Ferraresi V, Arance A, Guida M, Maiello E, Gogas H, Richtig E, Quaglino P, Lebbé C, Helgadottir H, Queirolo P, Spagnolo F, Tucci M, Del Vecchio M, Gonzalez-Cao M, Minisini A, De Placido S, Sanmamed M, Casula M, Bulgarelli J, Pisano M, Piccinini C, Piccin L, Cossu A, Mallardo D, Paone M, Vitale M, Melero I, Grimaldi A, Giannarelli D, Palmieri G, Dummer R, Sileni V. Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma. NEJM Evidence 2024, 3: evidoa2400087. PMID: 39315864, DOI: 10.1056/evidoa2400087.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitionBrain metastasesBRAF/MEK inhibitorsArm BArm AProgressive diseaseCheckpoint inhibitionBrain metastases-free survivalImmune checkpoint inhibitor ipilimumabMetastases-free survival ratesDevelopment of brain metastasesCheckpoint inhibitor ipilimumabMetastases-free survivalUnresectable metastatic melanomaV600-mutant melanomaCheckpoint inhibitorsInhibitor ipilimumabMetastatic melanomaBRAF/MEK inhibitionArm CReviewed patientsBRAF/MEKThree-arm trialEncorafenibFollow-upMHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers
Eguren-Santamaria I, de Piérola E, Camps G, Martín-Muñoz P, Campos M, Cuculescu D, Aguilera-Buenosvinos I, López I, Salido-Vallejo R, Alexandru R, De Andrea C, Álvarez-Gigli L, Berraondo P, Melero I, Sanmamed M. MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers. Journal For ImmunoTherapy Of Cancer 2024, 12: e008516. PMID: 39244214, PMCID: PMC11381650, DOI: 10.1136/jitc-2023-008516.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsHuman peripheral blood mononuclear cellsT-cell engagersNSG miceMajor histocompatibility complexSevere XGVHDImmunodeficient miceAntitumor effectTumor rejectionImmunotherapy agentsAntitumor activityAntitumor efficacy of immune checkpoint inhibitorsEfficacy of immune checkpoint inhibitorsHT29 human colon carcinoma cellsLong-term antitumor efficacyDevelopment of cancer immunotherapyAdministration of nivolumabImmune checkpoint inhibitorsCancer immunotherapy agentsT cell clonesHuman colon carcinoma cellsAlanine aminotransferase levelsMajor histocompatibility complex class IBlood mononuclear cellsHuman immune cells670P Phase I trial of the delta-like ligand-3 (DLL3)/CD3 IgG-Like T cell engager BI 764532 in patients (pts) with DLL3-positive tumors: Updated data
Wermke M, Gambardella V, Kuboki Y, Felip E, Sanmamed M, Alese O, Sayehli C, Aperribay E, Wolf J, Villaruz L, Studeny M, Bouzaggou M, Fang X, Morgensztern D. 670P Phase I trial of the delta-like ligand-3 (DLL3)/CD3 IgG-Like T cell engager BI 764532 in patients (pts) with DLL3-positive tumors: Updated data. Annals Of Oncology 2024, 35: s525-s526. DOI: 10.1016/j.annonc.2024.08.736.Peer-Reviewed Original ResearchCN59 Activity and outcomes of a Translational Research Unit coordinated by nursing
Andueza M, Zabalza E, Barberena Y, Burgui M, Ilundain I, Andueza I, Perea A, Andueza M, Sanmamed M, RodrÍguez-Ruiz M, Pio R, Hernandez A, Fortuño M, de Torres J, Maceiras L, Lozano M, Melero I, Montuenga L, Gracia J, Ocon M. CN59 Activity and outcomes of a Translational Research Unit coordinated by nursing. Annals Of Oncology 2024, 35: s1186. DOI: 10.1016/j.annonc.2024.08.463.Peer-Reviewed Original ResearchThyroid dysfunction caused by immune checkpoint inhibitors improves cancer outcomes.
García-Goñi M, Vázquez Gutiérrez B, Sanmamed M, Martín-Algarra S, Luis Pérez-Gracia J, Olmedo M, Chumbiauca E, Martín-Calvo N, Galofré J. Thyroid dysfunction caused by immune checkpoint inhibitors improves cancer outcomes. Endocrine Related Cancer 2024, 31 PMID: 39013402, DOI: 10.1530/erc-24-0064.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsImmune-related adverse eventsRisk of progressionOverall survivalPrimary tumorThyroid dysfunctionPatients treated with immune checkpoint inhibitorsCancer patients treated with immune checkpoint inhibitorsAssociated with higher ORRImmune checkpoint inhibitor regimenTreated with atezolizumabLonger overall survivalCox proportional hazards modelsResponse to treatmentProbability of recurrenceMultivariable-adjusted regressionRisk of mortalityProportional hazards modelIndependent of ageCheckpoint inhibitorsRECIST v1.1Higher ORRCombination therapyUrothelial cancerClinical presentationProtein Biomarkers in Lung Cancer Screening: Technical Considerations and Feasibility Assessment
Orive D, Echepare M, Bernasconi-Bisio F, Sanmamed M, Pineda-Lucena A, de la Calle-Arroyo C, Detterbeck F, Hung R, Johansson M, Robbins H, Seijo L, Montuenga L, Valencia K. Protein Biomarkers in Lung Cancer Screening: Technical Considerations and Feasibility Assessment. Archivos De Bronconeumología 2024, 60: s67-s76. PMID: 39079848, DOI: 10.1016/j.arbres.2024.07.007.Peer-Reviewed Original ResearchLung cancer screeningLung cancerCancer screeningManagement of lung cancerLDCT-based lung cancer screeningSurgically resected tumorsPresence of metastasesEarly lung cancerCancer-related deathsLung cancer patientsContext of lung cancer screeningDiagnosis to earlier stagesProtein biomarkersResected tumorProtein-based biomarkersTherapeutic optionsAdjuvant strategiesLate diagnosisCancer patientsRecommended management strategiesEarly managementLung cancer detectionRobust biomarkersBenefit patientsCancer